Manufacturer of Controlled Substances; Notice of Application, 53721-53722 [2010-21772]
Download as PDF
<![CDATA[
53721
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 1, 2010.
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–21775 Filed 8–31–10; 8:45 am]
[FR Doc. 2010–21773 Filed 8–31–10; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Application
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 14, 2010,
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 4, 2010,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
[FR Doc. 2010–21776 Filed 8–31–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 27, 2010,
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
hsrobinson on DSK69SOYB1PROD with NOTICES
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Methadone Intermediate (9254) ...
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 1, 2010.
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
4–Methoxyamphetamine (7411) ...
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 1, 2010.
PO 00000
Frm 00092
Fmt 4703
Drug
Schedule
Sfmt 4703
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Dextropropoxyphene, bulk ...........
(non-dosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Raw Opium (9600) .......................
Opium extracts (9610) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Poppy Straw (9650) .....................
Oxymorphone (9652) ...................
Concentrate of Poppy Straw
(9670).
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 1, 2010.
E:\FR\FM\01SEN1.SGM
01SEN1
53722
Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Coventry, Rhode Island 02816, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
[FR Doc. 2010–21772 Filed 8–31–10; 8:45 am]
BILLING CODE 4410–09–P
Drug
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 14, 2010,
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedule II:
Drug
Schedule
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL),8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 1, 2010.
Dated: August 13, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Tetrahydrocannabinols (7370) .....
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Fentanyl (9801) ............................
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for conversion and sale to dosage form
manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Rhodes Technologies to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Rhodes Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–21782 Filed 8–31–10; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2010–21744 Filed 8–31–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
hsrobinson on DSK69SOYB1PROD with NOTICES
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 16, 2010, and
published in the Federal Register on
March 24, 2010, (75 FR 14189),
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by letter to the Drug
By Notice dated March 16, 2010, and
published in the Federal Register on
March 24, 2010, (75 FR 14189), Rhodes
Technologies, 498 Washington Street,
VerDate Mar<15>2010
18:24 Aug 31, 2010
Jkt 220001
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Amphetamine (1100), a basic class of
controlled substance listed in schedule
II.
The company plans to acquire the
listed controlled substance in bulk from
a domestic source in order to
manufacture other controlled substances
in bulk for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Archimica, Inc., to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated
Archimica, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: August 13, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–21780 Filed 8–31–10; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL SCIENCE FOUNDATION
Proposal Review; Notice of Meetings
In accordance with the Federal
Advisory Committee Act (Pub. L. 92–
463, as amended), the National Science
Foundation (NSF) announces its intent
to hold proposal review meetings
throughout the year. The purpose of
these meetings is to provide advice and
recommendations concerning proposals
submitted to the NSF for financial
support. The agenda for each of these
meetings is to review and evaluate
proposals as part of the selection
process for awards. The review and
evaluation may also include assessment
of the progress of awarded proposals.
The majority of these meetings will take
place at NSF, 4201 Wilson Blvd.,
Arlington, Virginia 22230.
These meetings will be closed to the
public. The proposals being reviewed
include information of a proprietary or
confidential nature, including technical
information; financial data, such as
E:\FR\FM\01SEN1.SGM
01SEN1
]]>Agencies
[Federal Register Volume 75, Number 169 (Wednesday, September 1, 2010)]
[Notices]
[Pages 53721-53722]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-21772]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 4, 2010, Cambrex Charles
City, Inc., 1205 11th Street, Charles City, Iowa 50616, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Phenylacetone (8501)....................... II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Dextropropoxyphene, bulk................... II
(non-dosage forms) (9273)..................
Morphine (9300)............................ II
Thebaine (9333)............................ II
Raw Opium (9600)........................... II
Opium extracts (9610)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Poppy Straw (9650)......................... II
Oxymorphone (9652)......................... II
Concentrate of Poppy Straw (9670).......... II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than November 1, 2010.
[[Page 53722]]
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-21772 Filed 8-31-10; 8:45 am]
BILLING CODE 4410-09-P
